Onglyza: Advanced DPP-4 Inhibition for Type 2 Diabetes Control
| Product dosage: 5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 14 | $4.52 | $63.25 (0%) | 🛒 Add to cart |
| 28 | $4.30 | $126.50 $120.48 (5%) | 🛒 Add to cart |
| 42 | $4.16 | $189.76 $174.70 (8%) | 🛒 Add to cart |
| 56 | $4.02 | $253.01 $224.90 (11%) | 🛒 Add to cart |
| 84 | $3.92 | $379.51 $329.31 (13%) | 🛒 Add to cart |
| 112 | $3.82 | $506.02 $427.71 (15%) | 🛒 Add to cart |
| 140 | $3.61
Best per pill | $632.52 $506.02 (20%) | 🛒 Add to cart |
Onglyza (saxagliptin) is an oral antihyperglycemic agent indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. As a selective dipeptidyl peptidase-4 (DPP-4) inhibitor, it enhances the body’s natural ability to regulate blood glucose by increasing the concentration of active incretin hormones. This mechanism supports glucose-dependent insulin secretion and suppression of glucagon release, offering a targeted approach to managing hyperglycemia without increasing the risk of hypoglycemia when used as monotherapy. Clinicians value its complementary action when combined with other antidiabetic agents, providing a versatile option in personalized treatment regimens.
Features
- Contains saxagliptin hydrochloride as the active pharmaceutical ingredient
- Available in 2.5 mg and 5 mg film-coated tablets
- Once-daily dosing regimen supports adherence
- Does not require dose adjustment for meals
- Manufactured under current Good Manufacturing Practices (cGMP)
- Packaged in high-density polyethylene (HDPE) bottles with child-resistant caps
Benefits
- Enhances glucose-dependent insulin secretion for improved glycemic control
- Reduces hemoglobin A1c (HbA1c) levels effectively with once-daily administration
- Low intrinsic risk of hypoglycemia when not combined with sulfonylureas or insulin
- Supports weight neutrality, an advantage over some other antidiabetic therapies
- Provides complementary efficacy when used in combination with metformin, sulfonylureas, or thiazolidinediones
- Offers renal dosing flexibility with adjusted regimens for patients with impaired kidney function
Common use
Onglyza is commonly prescribed for the management of type 2 diabetes mellitus in adult patients. It is frequently utilized as monotherapy in individuals who cannot tolerate metformin or as add-on therapy when metformin alone does not provide adequate glycemic control. Clinicians may also combine it with sulfonylureas, thiazolidinediones, or insulin to achieve target HbA1c levels. Its use is particularly appropriate for patients who would benefit from a medication with a low risk of hypoglycemia and weight gain.
Dosage and direction
The recommended dosage of Onglyza is 5 mg taken orally once daily, with or without food. For patients with moderate to severe renal impairment (creatinine clearance ≤50 mL/min) or end-stage renal disease requiring hemodialysis, the dosage should be reduced to 2.5 mg once daily. No dosage adjustment is required for patients with hepatic impairment. Tablets should be swallowed whole and not crushed, split, or chewed. Blood glucose monitoring should be performed as directed by a healthcare provider to assess therapeutic response.
Precautions
Patients should be advised that Onglyza is not indicated for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis. Use with caution in patients with a history of pancreatitis; discontinue promptly if pancreatitis is suspected. Monitor renal function periodically, as dosage adjustment is necessary in renal impairment. There have been postmarketing reports of severe and disabling arthralgia; consider discontinuation if symptoms occur. Hypersensitivity reactions such as urticaria, angioedema, or anaphylaxis have been reported. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Contraindications
Onglyza is contraindicated in patients with a history of serious hypersensitivity reaction to saxagliptin or any component of the formulation, including anaphylaxis, angioedema, or severe cutaneous adverse reactions. It should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.
Possible side effect
Common adverse reactions (≥5%) include upper respiratory tract infection, urinary tract infection, and headache. Other reported side effects include nasopharyngitis, sinusitis, abdominal pain, vomiting, and peripheral edema. Hypoglycemia may occur when used in combination with sulfonylureas or insulin. Less common but serious adverse effects include acute pancreatitis, severe joint pain, heart failure (especially when used with thiazolidinediones), and hypersensitivity reactions. Patients should report any unusual symptoms to their healthcare provider promptly.
Drug interaction
Saxagliptin is primarily eliminated renally and is a substrate of CYP3A4/5. Strong CYP3A4/5 inhibitors (e.g., ketoconazole, atazanavir, clarithromycin) may increase saxagliptin exposure; consider reducing the Onglyza dose to 2.5 mg once daily when coadministered. Inducers of CYP3A4/5 may decrease saxagliptin concentrations. No clinically significant interactions have been observed with metformin, glyburide, pioglitazone, digoxin, simvastatin, or diltiazem. Monitor blood glucose when adding or discontinuing drugs that may affect glycemic control (e.g., corticosteroids, thyroid products).
Missed dose
If a dose of Onglyza is missed, it should be taken as soon as remembered on the same day. However, if it is almost time for the next scheduled dose, the missed dose should be skipped and the regular dosing schedule resumed. Patients should not take a double dose to make up for a missed one. Consistent daily administration is important for maintaining glycemic control.
Overdose
In the event of an overdose, supportive measures should be instituted based on the patient’s clinical presentation. Removal of saxagliptin by hemodialysis may be considered; approximately 23% of the dose is removed over a 4-hour hemodialysis session. Hypoglycemia may occur if Onglyza is taken in combination with other antidiabetic medications; treat with appropriate carbohydrate intake or glucagon as needed. There is no specific antidote for saxagliptin overdose.
Storage
Store Onglyza tablets at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F). Keep the bottle tightly closed and protect from moisture and light. Keep out of reach of children and pets. Do not use beyond the expiration date printed on the packaging.
Disclaimer
This information is intended for educational purposes and does not replace professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or treatment. Do not disregard professional medical advice or delay in seeking it because of something you have read in this product card. The prescribing information provided here may not include all possible uses, directions, precautions, or interactions.
Reviews
Clinical trials have demonstrated Onglyza’s efficacy in reducing HbA1c by approximately 0.4% to 0.9% as monotherapy and in combination with other antidiabetic agents. In a 24-week study, 44% of patients achieved an HbA1c <7% when using saxagliptin plus metformin compared to 17% with metformin alone. Healthcare providers report satisfaction with its tolerability profile and once-daily dosing convenience. Some real-world evidence suggests careful patient selection is important, particularly regarding cardiovascular risk assessment. Overall, it remains a valued option in the type 2 diabetes treatment arsenal, particularly for patients requiring additional glycemic control with a favorable side effect profile.